Please assess the completion status of the following clinical trial:

Trial Title: Non-inferiority of PRO-122 Ophthalmic Solution vs KRYTANTEK Ofteno® in Glaucoma or Ocular Hypertension (CONFORTK)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* male or female.~* obtained in the external consultation.~* With diagnosis primary of open-angle glaucoma and / or hypertension classified as mild, moderate or severe glaucomatous damage, users of Krytantek Ofteno® at least two months prior to inclusion and under control of the target IOP.~* informed consent.~Exclusion Criteria:~General Criteria~1. Subjects with topical or systemic medication that interferes decisively in the results of the study. (Such as topical immunomodulators, lacrimal point tamponade, corticosteroids, ocular hypotensives other than those listed above, artificial tears with preservative).~2. Subjects (female) with an active sex life who are not using a contraceptive method.~3. Female Subjects in pregnancy or breastfeeding.~4. Female subjects with positive urine pregnancy test.~5. Positive drug addiction (verbal interrogation).~6. Subjects who have participated in any clinical research study in the last 40 days.~7. Legally or mentally disabled subjects to give informed consent for their participation in this study.~8. Subjects who can not comply with the appointments or with all the requirements of the protocol.~Ophthalmologic criteria~1. Subject with only one eye with vision.~2. Subjects with visual capacity 20/200 or worse.~3. Subjects with a narrow-angle history without treatment, with or without total or partial closure of the angle in either eye.~4. Subjects with corneal abnormalities that prevent applanation tonometry.~5. Subjects with ocular surgery or ocular trauma 6 months prior to inclusion.~6. Any ocular laser surgery 3 months prior.~7. Any uncontrolled or progressive retinal disease.~8. Inflammatory diseases of any kind.~9. Contact lens wearers.~10. Subjects with a history of hypersensitivity to any of the ingredients of the research product or its analogues.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: OTHER): In group A, therapy with Krytantek Ofteno® will be continued for 30 days, in which the subject will be retested and switched to a PRO-122 solution which will be used for 30 days until the 60th day, The final visit.
- Group B (Type: OTHER): In group B, therapy with Krytantek Ofteno® will be suspended and changes for PRO-122 for 30 days, in which the subject will be retested and later switched to Krytantek Ofteno® solution which will be used for 30 days until the 60th day, The final visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).